Israeli startup PhaseV, an AI-enabled clinical development company for life sciences, has secured $50 million in Series A funding in a round co-led by Accel and Insight Partners. Existing investors Viola Ventures, LionBird and EXOR…
Continue Reading
What You Should Know:
– PhaseV, a company at the forefront of applying artificial intelligence (AI) and machine learning (ML) to clinical development raies $50M in Series A funding round co-led by Accel and Insight…
Continue Reading
A clinical trial can cost hundreds of millions of dollars, and one of the major contributors to costs is recruiting and keeping human subjects. According to Dr. Raviv Pryluk, PhD, CEO and co-founder at…
Continue Reading
A clinical trial can cost hundreds of millions of dollars, and one of the major contributors to costs is recruiting and keeping human subjects. According to Dr. Raviv Pryluk, PhD, CEO and co-founder at…
Continue Reading
Clinical Trial Platform Uncovers Hidden Signals and Optimizes Next Steps for More Adaptive, Successful, and Efficient Clinical Trials
PhaseV, a pioneer in causal machine learning (ML) technology that optimizes clinical trial design and analysis, announced today that it has…
